// App-Quantinova.ai

982 : VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo

Researchers

Presenter

  • Winnie F. Tam

Principal Investigators

  • Jennifer E. Ring

  • Anthony F. Trombino

  • David T. Weaver

  • Jonathan A. Pachter

  • Mahesh Padval

  • Qunli Xu

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Verastem, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute promyelocytic leukemia

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Focal Adhesion Kinase

Drug/Treatment

  • VS4718

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved